Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Heinz Gisslinger, MD, Christoph Klade, Pencho Georgiev, Aleksander Skotnicki, MD PhD, Liana Gercheva-Kyuchukova, MD, Miklos Egyed, Viktor Rossiev, MD, Petr Dulicek, Arpad Illes, MD PhD, Halyna Pylypenko, MD, Liliya Sivcheva, Jiri Mayer, MD, Barbara Grohmann-Izay, MD, Hans Hasselbalch, MD, Robert Kralovics, Jean-Jacques Kiladjian, MD PhD

Blood (2016) 128 (22): 475.

https://doi.org/10.1182/blood.V128.22.475.475

Published: 2016

Journal Articles

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Blood (2016) 128 (5): 630–637.

https://doi.org/10.1182/blood-2016-01-687434

Published: 2016

Includes: Supplemental data

Journal Articles

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

Blood (2016) 127 (3): 360–362.

https://doi.org/10.1182/blood-2015-08-662130

Published: 2016

Includes: Supplemental data

Journal Articles

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

Tadeusz Robak, Jerzy Z. Blonski, MD, PhD, Krzysztof Jamroziak, MD, PhD, Aleksander Skotnicki, Professor, Magdalena Piotrowska, MD, Anatoly Uss, Professor, Janusz Kloczko, Professor, Jaroslaw Piszcz, Kazimierz Kuliczkowski, Professor, Tomasz Wrobel, MD PhD, Bozena Katarzyna Budziszewska, MD, PhD, Marta Fidecka, Piotr Smolewski, Professor

Blood (2013) 122 (21): 1640.

https://doi.org/10.1182/blood.V122.21.1640.1640

Published: 2013

Journal Articles

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Bastian von Tresckow, MD, Aleksander Skotnicki, MD, PhD, Igur Lisukov, MD, Shivani Srivastava, MD, David S. Morgan, MD, Franck Morschhauser, MD, PhD, Caterina Stelitano, Jeffrey Szer, BMedSc, MBBS, FRACP, Dennis A. Eichenauer, MD, Jeremy S. Abramson, MD, Anna Sureda, MD, PhD, Christophe Ferme, MD, Andreas Engert, MD

Blood (2013) 122 (21): 4648.

https://doi.org/10.1182/blood.V122.21.4648.4648

Published: 2013

Journal Articles

Diabetes Mellitus Compromises Survival of Young Non Hodgkin Lmphoma Patients Treated with (R) CHOP Chemotherapy - a Retrospective Multicenter Analysis by Polish Lymphoma Study Group

Wojciech Jurczak, Joanna E Drozd-Sokolowska, Monika Joks, Justyna Dzietczenia, Tomasz Wrobel, Beata Kumiega, Jan Maciej Zaucha, Wanda Knopinska-Posluszny, Wojciech Spychalowicz, Agnieszka Giza, Maciej J Machaczka, Aleksander Skotnicki, MD PhD

Blood (2012) 120 (21): 4844.

https://doi.org/10.1182/blood.V120.21.4844.4844

Published: 2012

Journal Articles

Clofarabine As the Element of Conditioning Regimen in Matched Related Allogeneic Transplantation – Single Center Experience

Patrycja Mensah-Glanowska, Beata Piatkowska-Jakubas, Aleksander Skotnicki, MD PhD

Blood (2012) 120 (21): 4516.

https://doi.org/10.1182/blood.V120.21.4516.4516

Published: 2012

Journal Articles

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Lidia Gil, MD PhD, Jan Styczynski, MD, PhD, Agnieszka Piekarska, MD PhD, Beata Jakubas, MD PhD, Katarzyna Drabko, MD PhD, Tomasz Wrobel, prof., Anna Czyz, MD PhD, Anna Lojko-Dankowska, MD PhD, Dominik Dytfeld, MD PhD, Adam Nowicki, MD, Patrycja Mensah-Glanowska, MD PhD, Wanda Knopinska-Posluszny, MD, PhD, Maria Bieniaszewska, MD PhD, Mariusz Wysocki, MD, PhD, Andrzej Hellmann, MD, PhD, Aleksander Skotnicki, Jerzy Kowalczyk, Kazimierz Kuliczkowski, MD PhD, prof., Mieczyslaw Komarnicki, MD PhD

Blood (2011) 118 (21): 3109.

https://doi.org/10.1182/blood.V118.21.3109.3109

Published: 2011

Journal Articles

Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study,

Blood (2011) 118 (21): 3915.

https://doi.org/10.1182/blood.V118.21.3915.3915

Published: 2011

Journal Articles

High Incidence of Cardiovascular Complications After CHOP-Like Chemotherapy In Lymphoma Patients From Poland – Retrospective Analysis of Polish Lymphoma Research Group (PLRG)

Wojciech Jurczak, Marcin Sobocinski, Jagoda Gorka, Jacek Cieslak, Joanna Drozd-Sokolowska, Piotr Boguradzki, Justyna Dzietczenia, Monika Joks, Andrzej Deptala, Magdalena Halasz, Tomasz Wrobel, MD, PhD, Grzegorz Mazur, Aleksander Skotnicki, MD, PhD

Blood (2010) 116 (21): 1764.

https://doi.org/10.1182/blood.V116.21.1764.1764

Published: 2010

Journal Articles

Liposomal Cytarabine (DepoCyte) Is Effective and Well Tolerated In Prophylaxis of Central Nervous System (CNS) Relapse of High Risk Lymphoma Patients

Wojciech Jurczak, Justyna Dzietczenia, Beata Piatkowska-Jakubas, Marcin Sobocinski, Tomasz Ogorka, Agnieszka Giza, Grzegorz Mazur, Tomasz Wrobel, MD, PhD, Aleksander Skotnicki, MD, PhD

Blood (2010) 116 (21): 4890.

https://doi.org/10.1182/blood.V116.21.4890.4890

Published: 2010

Journal Articles

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Blood (2010) 116 (21): 2138.

https://doi.org/10.1182/blood.V116.21.2138.2138

Published: 2010

Journal Articles

Status of Minimal Residual Disease Determines Outcome of Autologous HSCT in Adults with High-Risk Acute Lymphoblastic Leukemia.

Sebastian Giebel, Beata Stella-Holowiecka, Malgorzata Krawczyk-Kulis, Nicola Goekbuget, Dieter Hoelzer, Michael Doubek, Jiri Mayer, Beata Piatkowska-Jakubas, Aleksander Skotnicki, Herve Dombret, Josep-Maria Ribera, Pier Paolo Piccaluga, Tomasz Czerw, Maria Sadus-Wojciechowska, Slawomira Kyrcz-Krzemien, Jerzy Holowiecki

Blood (2009) 114 (22): 2321.

https://doi.org/10.1182/blood.V114.22.2321.2321

Published: 2009

Journal Articles

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

Blood (2008) 112 (11): 4301.

https://doi.org/10.1182/blood.V112.11.4301.4301

Published: 2008

Journal Articles

Significance of BAALC , MN 1, ERG , CEBP a Gene Expression as New Prognostic Factors, in the Context of Other Molecular Markers in Intermediate Risk AML Group According to Cytogenetics, Including Patients Younger Than 60 Years

Marta Antonina Libura, MD, PhD, Beata Piatkowska-Jakubas, Olga Haus, Izabela Florek, Bozena Jazwiec, PhD, Krystyna Soszynska, PhD, Zoriana Salamanchuk, PhD, Malgorzata Jakobczyk, Szymon Fornagiel, Tomasz Sacha, Marek Kielbinski, Kazimierz Kuliczkowski, Ewa Duszenko, Anna Jaskowiec, Barbara Mucha, Katarzyna Skonieczna, Aleksander Skotnicki

Blood (2008) 112 (11): 4855.

https://doi.org/10.1182/blood.V112.11.4855.4855

Published: 2008

Journal Articles

Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).

Blood (2008) 112 (11): 2103.

https://doi.org/10.1182/blood.V112.11.2103.2103

Published: 2008

Journal Articles

High-Dose Therapy Followed by Autologous HSCT in Patients with Multiple Myeloma. Results of a Retrospective Multicenter Analysis Conducted by The Polish Myeloma Group.

Wanda M. Knopinska-Posluszny, MD, PhD, Andrzej Hellmann, Michal Taszner, MD, Anna Dmoszynska, Wiktor Jedrzejczak, Jerzy Holowiecki, Jan Walewski, Krzysztof Warzocha, Aleksander Skotnicki, Andrzej Lange, Kazimierz Kuliczkowski, Kazimierz Sulek, M. Komarnicki, Tadeusz Robak

Blood (2007) 110 (11): 5108.

https://doi.org/10.1182/blood.V110.11.5108.5108

Published: 2007

Journal Articles

Cytoprotective Effect of Palifermin on Gastrointestinal Mucous Membrane Enabled Non-Myeloablative Chemotherapy Administration in ALL Patient with High Risk of Gastrointestinal Toxicity.

Kajetana Foryciarz, MD, Tomasz Sacha, MD PhD, Patrycja Mensah-Glanowska, MD PhD, Agnieszka Balana-Nowak, PhD, Aleksander Skotnicki

Blood (2007) 110 (11): 4332.

https://doi.org/10.1182/blood.V110.11.4332.4332

Published: 2007

Journal Articles

Minimal Residual Disease Status Is the Most Important Preditive Factor in Adults with Acute Lymphoblastic Leukemia. Prospective, Multicenter PALG 4-2002 MRD Study.

Jerzy Holowiecki, Malgorzata Krawczyk-Kulis, Sebastian Giebel, Krystyna Jagoda, Beata Stella-Holowiecka, Beata Jakubas, Monika Paluszewska, Ilona Seferynska, Anna Czyz, Wlodzimierz Mendrek, Aleksander Skotnicki, Wieslaw W. Jedrzejczak, Krzysztof Warzocha, Lech Konopka, Andrzej Hellmann

Blood (2007) 110 (11): 2821.

https://doi.org/10.1182/blood.V110.11.2821.2821

Published: 2007

Journal Articles

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Hagop Kantarjian, Ricardo Pasquini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Holowiecki, Saengsuree Jootar, Tadeusz Robak, Nina Khoroshko, Tamas Masszi, Aleksander Skotnicki, Andrzej Hellmann, Andrey Zaritsky, Anatoly Golenkov, Jerald Radich, Timothy Hughes, Athena Countouriotis, Neil Shah

Blood (2007) 109 (12): 5143–5150.

https://doi.org/10.1182/blood-2006-11-056028

Published: 2007

NARROW

Final Results from PROUD-PV a Randomized Controlled Phase 3 Trial Comparing Ropeginterferon Alfa-2b to Hydroxyurea in Polycythemia Vera Patients

Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3 -ITD + normal karyotype AML patients

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation

Diabetes Mellitus Compromises Survival of Young Non Hodgkin Lmphoma Patients Treated with (R) CHOP Chemotherapy - a Retrospective Multicenter Analysis by Polish Lymphoma Study Group

Clofarabine As the Element of Conditioning Regimen in Matched Related Allogeneic Transplantation – Single Center Experience

Role of Second Stem Cell Transplantation in Relapsed Lymphoproliferative Diseases: Remission Status Is the Most Important Factor Predicting the Outcome

Cladribine Alone and in Combination with Cyclophosphamide or Cyclophosphamide and Mitoxantrone in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Long-Term Follow-up of the the Polish Adult Leukemia Group (PALG CLL2) Study,

High Incidence of Cardiovascular Complications After CHOP-Like Chemotherapy In Lymphoma Patients From Poland – Retrospective Analysis of Polish Lymphoma Research Group (PLRG)

Liposomal Cytarabine (DepoCyte) Is Effective and Well Tolerated In Prophylaxis of Central Nervous System (CNS) Relapse of High Risk Lymphoma Patients

Improved Outcome of Adult Acute Lymphoblastic Leukemia Treated with Individualized Protocol Adjusted to the Status of Minimal Residual Disease and Age. Interim Analysis of PALG ALL 5–2007 Study

Status of Minimal Residual Disease Determines Outcome of Autologous HSCT in Adults with High-Risk Acute Lymphoblastic Leukemia.

Palifermin Does Not Influence the Incidence and Severity of GvHD Nor Long-Term Survival of Patients with Hematological Diseases Undergoing HSCT

Significance of BAALC , MN 1, ERG , CEBP a Gene Expression as New Prognostic Factors, in the Context of Other Molecular Markers in Intermediate Risk AML Group According to Cytogenetics, Including Patients Younger Than 60 Years

Randomized Comparison of Cladribine Plus Cyclophosphamide with Fludarabine Plus Cyclophosphamde in Untreated Patients with Chronic Lymphocytic Leukemia: Report of the Polish Adult Leukemia Group (PALG-CLL3).

High-Dose Therapy Followed by Autologous HSCT in Patients with Multiple Myeloma. Results of a Retrospective Multicenter Analysis Conducted by The Polish Myeloma Group.

Cytoprotective Effect of Palifermin on Gastrointestinal Mucous Membrane Enabled Non-Myeloablative Chemotherapy Administration in ALL Patient with High Risk of Gastrointestinal Toxicity.

Minimal Residual Disease Status Is the Most Important Preditive Factor in Adults with Acute Lymphoblastic Leukemia. Prospective, Multicenter PALG 4-2002 MRD Study.

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only